

Ad | Business Infoline

U.S. markets closed

S&P 500
4,400.27
-47.81 (-1.07%)



Dow 30
34,960.69
-382.59 (-1.08%)



Nasdaq
14,525.91
-130.27 (-0.89%)



Russell 2000
2,158.78
-18.39 (-0.84%)



Crude Oil
64.45
-2.14 (-3.27%)



Gold
1,790.00
+2.20 (+0.12%)

VISION

Diamond Therapeutics Announces Health Canada Approval of Clinical Trial with Low-Dose Psilocybin



Tue, August 17, 2021, 5:12 AM



TORONTO, Aug. 17, 2021 /CNW/ - Diamond Therapeutics Inc. ("Diamond"), a drug development company focused on low-dose psychedelic therapies for use in the treatment of mental health, is pleased to announce that it has received a No Objection Letter from Health Canada, allowing Diamond to proceed with a human clinical trial to evaluate low doses of psilocybin in healthy volunteers.




Diamond Therapeutics Inc. Logo (CNW Group/Diamond Therapeutics Inc.)

The trial is a Phase 1 randomized, placebo-controlled, double-blind study to evaluate the safety and pharmacokinetics of low doses of psilocybin in as many as 80 study participants.

According to Health Canada's clinical trials database, to date, there are only two other Canadian clinical trials involving psilocybin.

"We are grateful to Health Canada for their support of this groundbreaking study," says Judy Blumstock, CEO of Diamond.



Quote Lookup

TRENDING

1. Tories Pounce After Trudeau Says Monetary Policy Not a Priority
2. New York to Boston Needs to Watch Tropical Storm Henri
3. UK court sets scene for \$14 bln-plus class action against Mastercard
4. Biden Pushes for Masks in Schools; Cigna Mandate: Virus Update
5. U.S. disaster chief says vaccination rates are rising in hurricane-prone states

potential for therapeutic use. Diamond believes these findings may help unlock the use of low-dose psilocybin to treat psychiatric disorders, including anxiety and depression.

"This upcoming clinical trial will enable Diamond to gain critical clinical information that will help inform future human trials with psilocybin and other pipeline compounds," says Dr. Edward Sellers, chair of Diamond's scientific advisory board.

Diamond is also planning to launch a Phase 2 trial to investigate low-dose psilocybin's efficacy in treating anxiety, which is the most common mental health disorder in the U.S., causing moderate to severe disability in over 50% of sufferers. This Phase 2 study will be conducted in both Canada and the U.S.

As well, Diamond plans to support an investigator-led study of low-dose psilocybin in the U.S. to explore its effects on patients with moderate depression.

"We're very excited to commence our clinical program. It brings us one step closer to creating therapeutics that can

Story continues



ATMA Journey Centers Inc. ("ATMA"), an Alberta-based company focused on delivering innovative psychedelic-assisted therapies internationally, announced today their submission of the first experiential-based clinical...
1d ago

Motley Fool

Here's Why Johnson & Johnson's Vaccine Could Overtake Both Pfizer and Moderna

Johnson & Johnson's (NYSE: JNJ) COVID-19 vaccine has had some challenges this year. Vaccines from Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) have generated far more revenue for those companies...
8h ago

Ad • The Motley Fool Canada

Apple Car Could Make This TSX Stock Skyrocket

This Canadian Dark Horse is Rumored to be Building Apple Car.

Benzinga

Why AzurRx Stock Is Trading Higher After MS1819 Combo Therapy Data?

AzurRx BioPharma Inc (NASDAQ: AZRX) has announced topline results from its Phase 2 Combination Trial evaluating MS1819 with porcine-derived pancreatic enzyme replacement therapy (PERT) for severe exocrine...
10h ago

Investor's Business Daily

Vaccine Stocks Fall After U.S. Officials Recommend Covid Booster Shots

Vaccine stocks fell Wednesday after the Biden administration recommended booster shots for recipients of mRNA vaccines.

2h ago

Eat This, Not That!

Delta Symptoms Usually Appear Like This

With a variant that's as contagious as chickenpox—and in fact twice as contagious as the variants before it—knowing if you caught COVID is essential. After all, you want to seek care ASAP—and don't want to pass i...

1d ago

Ad • True Market Insiders

Man Who Predicted 2020 Crash Issues Huge Warning

Wall street insider Chris Rowe says, "fortunes will be made, and lost... in what will go down as the greatest stock market event in the last 20 years."

MarketWatch

Who can get a COVID booster shot, and where do you get one? Here's what we know so far

After months of speculation about COVID-19 booster shots, public health officials are rolling out a plan to get fully vaccinated Americans another shot in the arm as early as next month. Federal health officials announced...
4h ago

Yahoo Finance

Biden, Fauci, CDC director support COVID-19 booster shots

White House officials recommend a third dose for mRNA vaccine recipients to battle the latest COVID-19 surge.

Regeneron Stock Jumps as GOP Governors Boost Its

CEO Leonard Schleifer said that utilization of the therapy, which has lagged so far during the... 7h ago

Ad • The Daily Distraction

Weather Girl Announces She Quits On Air

She no longer needs to work

Barrons.com

CureVac Says Second Covid-19 Vaccine Was Better in Preclinical Test

CureVac and partner GlaxoSmithKline say CureVac's second-generation Covid-19 vaccine was more effective than its first in a test with monkeys. CureVac's first vaccine was a disappointment.

1d ago

GlobeNewswire

Cidara Therapeutics and Mundipharma Announce Completion of Enrollment in the Phase 3 ReSTORE Trial of Rezafungin for the

Top-line data anticipated in late 2021 Single Phase 3 trial serves as basis for global regulatory filings SAN DIEGO and CAMBRIDGE, England, Aug. 17, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) and...

1d ago

Motley Fool

3 Beaten-Down Biotech Stocks to Buy Right Now

Volatility comes with the territory when you invest in biotech stocks. Here's why they chose Bluebird Bio (NASDAQ: BLUE), Lucira Health (NASDAQ: LHDX), and Vertex Pharmaceuticals (NASDAQ: VRTX). Prosper...

12h ago

Ad • Gundry MD

Heart Surgeon Drops 70 LBS: "I Quit Three Foods"

Top Surgeon and Author of the Best Selling Book "Dr. Gundry's Diet Evolution" Discovers Link Between Gut Health and the Rising Number on the Scale.

CBS News

Texas Governor Greg Abbott tests positive for COVID-19

Abbott is fully vaccinated and so far is experiencing no symptoms, his office said.

10h ago

Motley Fool

Why Pfizer and Moderna Won't Make As Much Extra Money From U.S. Booster Doses As You Might Think

For a while, both the Centers for Disease Control & Prevention (CDC) and the U.S. Food and Drug Administration (FDA) played down the need for third COVID-19 booster doses. On Aug. 12, the FDA updated the Emergenc...

1d ago

Ad • Market Tactic ...

Goldman Sachs Says Gold Will Surge 20% By Y/E

Global conditions sparked 2020's epic bonanza in gold mining stocks. And it looks as ...

Bloomberg

Biden Pushes for Masks in Schools; Cigna Mandate: Virus Update

(Bloomberg) -- Joe Biden's administration will start offering booster shots in late September, and will require nursing homes to vaccinate their staff against the coronavirus in order to receive federal funding. The president...

15m ago

Motley Fool

Here's What This Label Expansion Means for AstraZeneca Investors

The recent decision by the EMA to approve Forxiga for the treatment of chronic kidney disease is a huge boost for the pharmaceutical company.

1d ago

Yahoo Finance Canada

Older Canadian seniors to get an extra \$500 this week

They need to be eligible for Old Age Security in June 2021 and born on or before June 30, 1947.

1d ago

Ad • Investing.com Magazine ...

Tom Brady's New Yacht Is A Floating Mansion

Tom Brady Spent Half Of His New Contract To Buy This Yacht

BuzzFeed

Teens Are Drinking Half A Gallon Of Pineapple Juice Before Having Their Wisdom Teeth Removed — But Is It Safe?

"Pineapple has an enzyme called bromelain, [which] triggers your body's natural anti-inflammatory response."View Entire Post >

1d ago

The New York Times

In a Handful of States, Early Data Hint at a Rise in Breakthrough Infections

Since Americans first began rolling up their sleeves for coronavirus vaccines, health officials have said that those who are immunized are very unlikely to become infected, or to suffer serious illness or death. But...

10h ago

Motley Fool

Why Sesen Bio Stock Fell off a Cliff Monday

Such was the case with ambitious biotech Sesen Bio (NASDAQ: SESN), which saw its share price decline by a queasy 42% on Monday following continued fallout from a very discouraging communication from the FDA....

2d ago

